Genentech

Our Promise is our north star for ourselves, patients, and society. It builds upon our history of forging life-altering scientific breakthroughs and reminds us that we are on a bolder quest than ever before - to be courageous changemakers in solving the world’s most complex health challenges and improving the lives of all patients. http://spr.ly/6049V62k7

Small environmentally conscious food choices have been making a big impact on our San Francisco campus. By adjusting the default ordering to a plant-based alternative in our employee cafeterias, data from a pilot study revealed that meat consumption per transaction decreased by nearly 20%. This initiative is just one of many efforts underway to help us lower our environmental footprint by 50% by 2025: http://spr.ly/6046b5pp4

We prioritize diversity across all aspects of our business, which is why we’re ahead of schedule to reach our aspiration to invest $1B annually with diverse suppliers by 2025. In 2023 alone, we spent $964.2M with diverse suppliers, a $229M annual increase since 2020. This investment allows us to tap unique perspectives, develop the next generation of diverse STEM talent and better serve our communities. See how we’re helping businesses from historically marginalized communities thrive in our recently released D&I Annual Report: https://lnkd.in/g5Frv-RM

Today, 38 of our labs have achieved “My Green Lab” certification, a program recognized by the United Nations “Race to Zero” campaign as a key measure of progress towards a zero-carbon future. Our goal is to certify all labs by 2027. Through this certification, we’ve improved overall lab sustainability by an average of 30%, resulting in a reduction of CO2 emissions by 138 metric tons per year – equivalent to the annual electricity use of 27 U.S. homes! Learn more about our sustainability initiatives here: http://spr.ly/6045b5pZN #EarthDay2024 #InvestInOurPlanet

Today, the FDA approved our #targetedtherapy to treat ALK+ early-stage resected non-small cell lung cancer, marking the first treatment option available for this patient population. Biomarker testing is a critical step for early-stage lung cancer patients to ensure they receive the treatment appropriate for them. Learn more: https://bit.ly/3JqNUvU

#NationalMinorityHealthMonth serves as a reminder of the complex and deep-rooted disparities impacting communities nationwide – and eye health is no exception. But partnerships can strengthen our ability to address these complex challenges together. Read how we are breaking barriers to address diabetic eye disease: https://lnkd.in/gcvuhvJh #NMHM24

There are hundreds of neurological conditions impacting nearly 100 million Americans alone. Hear more from Gregory Rippon, Vice President and Chief Medical Partner of Neurology, about how we’re continuing to create a tomorrow where neurological disorders no longer impact the unique qualities that make people who they are. http://spr.ly/6046wUdPu #AANAM

We’re presenting new data from our Phase III study at #AANAM demonstrating the continued benefit of our investigational molecule for people living with relapsing and progressive multiple sclerosis. Learn more about our efforts to provide an additional therapy option for the community of patients we serve: https://lnkd.in/g9zsgpni

For us, inclusive research is not about checking a box, it’s about better serving patients and evolving the way we design and execute all clinical studies across our business. In 2023, we expanded our Advancing Inclusive Research (AIR) Site Alliance footprint, bringing clinical studies to more communities who have historically been left out. And we’re seeing real results. Our AIR Site Alliance sites are enrolling more diverse patient populations two times faster compared to their study peers. Check out our latest D&I Annual Report to learn more about how we’re setting industry standards for inclusive research: http://spr.ly/6041w4m85

Over the last 60+ years, we’ve harnessed technology and scientific insights to discover and develop medicines for the most common and rare neurological conditions. But, our work does not stop here. Learn how we’re evolving the neuroscience field through groundbreaking research, advancements in equitable access to care and community collaborations. http://spr.ly/6045wUdKP #AANAM